Tykerb lapatinib regulatory update

GlaxoSmithKline submitted an sNDA to FDA for Tykerb lapatinib as first-line treatment of hormone-sensitive, advanced or metastatic breast cancer in combination with anti-hormonal therapy. Additionally...